1,759 results on '"Rammensee, Hans-Georg"'
Search Results
202. Contributors
203. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
204. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
205. TLR9-independent and immune complex-independent interferon α production by neutrophils upon netosis in response to circulating chromatin
206. Peptide motif of HLA-B*1510
207. Chair's Introduction
208. The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis
209. Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases
210. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation
211. Chromatin-activated neutrophils represent a major source of interferon α
212. Integrin activation enables simultaneous and sensitive detection of functional virus-specific CD4+ and CD8+ T cells
213. Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
214. Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
215. Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus antibody test for the evaluation of cross-reactivity to endemic coronavirus antigens
216. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition
217. An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens
218. The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.
219. Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups
220. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
221. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies
222. Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture
223. Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models
224. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
225. IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY
226. PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
227. Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for pharmaceutical therapies
228. MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics
229. Targeting tumor-resident mast cells for effective anti-melanoma immune responses
230. Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial
231. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis
232. The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissues
233. The HLA-B* 1516 motif demonstrates HLA-B-specific P2 pocket characteristics
234. Cytotoxic minor histocompatibility antigen HA-1–specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction
235. Neurological symptoms in patients with biopsy proven celiac disease
236. Novel Multi-Peptide Vaccination In Hla-A2+ Hormone Sensitive Patients With Biochemical Relapse of Prostate Cancer
237. A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis
238. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1
239. EpiToolKit—a web server for computational immunomics
240. Das HLA-Ligandom und Identifizierung von tumorassoziierten Antigenen in Meningeomen - der erste Schritt Richtung Peptid-Vakzinierung in Meningeomen
241. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket
242. On the development of personalized cancer vaccines
243. MHC ligands and peptide motifs: first listing
244. Peptide motifs of HLA-B58, B60, B61, and B62 molecules
245. Peptides Made to Order
246. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus
247. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer
248. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs
249. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo
250. CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.